Coherus Surges After Six‑Year Survival Breakthrough for Tagmokitug
Coherus Oncology’s CCR8 antibody Tagmokitug shows a 15‑month survival boost, sparking a 12.4 % Nasdaq surge and signaling a possible shift from biosimilars to high‑margin oncology.
2 minutes to read